The European Medicines Agency has begun fast-track reviews of the EU marketing applications for sipavibart, AstraZeneca’s drug for preventing COVID-19 in immunocompromised patients, and dorocubicel, ExCellThera’s treatment for patients with hematological malignancies who need a stem cell transplant.
The two investigational drugs are among 11 new entries on the EMA’s latest monthly list of products for which...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?